Safety of intravenous tranexamic acid in patients undergoing major orthopaedic surgery: A meta-analysis of randomised controlled trials

Massimo Franchini, Carlo Mengoli, Marco Marietta, Giuseppe Marano, Stefania Vaglio, Simonetta Pupella, Pier Mannuccio Mannucci, Giancarlo M. Liumbruno

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

Among the various pharmacological options to decrease peri-operative bleeding, tranexamic acid appears to be one of the most interesting. Several trials have consistently documented the efficacy of this synthetic drug in reducing the risk of blood loss and the need for allogeneic blood transfusion in patients undergoing total hip and knee arthroplasty. The safety of intravenous tranexamic acid in major orthopaedic surgery, particularly regarding the risk of venous thromboembolism, was systematically analysed in this review. A systematic search of the literature identified 73 randomised controlled trials involving 4,174 patients and 2,779 controls. The raw overall incidence of venous thromboembolism was 2.1% in patients who received intravenous tranexamic acid and 2.0% in controls. A meta-analytic pooling showed that the risk of venous thromboembolism in tranexamic acid-treated patients was not significantly different from that of controls (risk difference: 0.01%, 95% confidence interval [CI]: -0.05%, 0.07%; risk ratio: 1.067, 95% CI: 0.760-1.496). Other severe drug-related adverse events occurred very rarely (0.1%). In conclusion, the results of this systematic review and meta-analysis show that intravenous tranexamic acid is a safe pharmacological treatment to reduce blood loss and transfusion requirements in patients undergoing major orthopaedic surgery.

Original languageEnglish
Pages (from-to)36-43
Number of pages8
JournalBlood Transfusion
Volume16
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Tranexamic Acid
Orthopedics
Meta-Analysis
Randomized Controlled Trials
Venous Thromboembolism
Safety
Blood Transfusion
Pharmacology
Confidence Intervals
Knee Replacement Arthroplasties
Drug-Related Side Effects and Adverse Reactions
Hip
Odds Ratio
Hemorrhage
Incidence
Pharmaceutical Preparations

Keywords

  • Orthopaedic surgery
  • Safety
  • Thromboembolic events.
  • Tranexamic acid

ASJC Scopus subject areas

  • Immunology and Allergy
  • Hematology

Cite this

Safety of intravenous tranexamic acid in patients undergoing major orthopaedic surgery : A meta-analysis of randomised controlled trials. / Franchini, Massimo; Mengoli, Carlo; Marietta, Marco; Marano, Giuseppe; Vaglio, Stefania; Pupella, Simonetta; Mannucci, Pier Mannuccio; Liumbruno, Giancarlo M.

In: Blood Transfusion, Vol. 16, No. 1, 01.01.2018, p. 36-43.

Research output: Contribution to journalReview article

@article{04bb7420a6854586a21bf3175e4d503e,
title = "Safety of intravenous tranexamic acid in patients undergoing major orthopaedic surgery: A meta-analysis of randomised controlled trials",
abstract = "Among the various pharmacological options to decrease peri-operative bleeding, tranexamic acid appears to be one of the most interesting. Several trials have consistently documented the efficacy of this synthetic drug in reducing the risk of blood loss and the need for allogeneic blood transfusion in patients undergoing total hip and knee arthroplasty. The safety of intravenous tranexamic acid in major orthopaedic surgery, particularly regarding the risk of venous thromboembolism, was systematically analysed in this review. A systematic search of the literature identified 73 randomised controlled trials involving 4,174 patients and 2,779 controls. The raw overall incidence of venous thromboembolism was 2.1{\%} in patients who received intravenous tranexamic acid and 2.0{\%} in controls. A meta-analytic pooling showed that the risk of venous thromboembolism in tranexamic acid-treated patients was not significantly different from that of controls (risk difference: 0.01{\%}, 95{\%} confidence interval [CI]: -0.05{\%}, 0.07{\%}; risk ratio: 1.067, 95{\%} CI: 0.760-1.496). Other severe drug-related adverse events occurred very rarely (0.1{\%}). In conclusion, the results of this systematic review and meta-analysis show that intravenous tranexamic acid is a safe pharmacological treatment to reduce blood loss and transfusion requirements in patients undergoing major orthopaedic surgery.",
keywords = "Orthopaedic surgery, Safety, Thromboembolic events., Tranexamic acid",
author = "Massimo Franchini and Carlo Mengoli and Marco Marietta and Giuseppe Marano and Stefania Vaglio and Simonetta Pupella and Mannucci, {Pier Mannuccio} and Liumbruno, {Giancarlo M.}",
year = "2018",
month = "1",
day = "1",
doi = "10.2450/2017.0219-17",
language = "English",
volume = "16",
pages = "36--43",
journal = "Blood Transfusion",
issn = "1723-2007",
publisher = "Edizioni SIMTI",
number = "1",

}

TY - JOUR

T1 - Safety of intravenous tranexamic acid in patients undergoing major orthopaedic surgery

T2 - A meta-analysis of randomised controlled trials

AU - Franchini, Massimo

AU - Mengoli, Carlo

AU - Marietta, Marco

AU - Marano, Giuseppe

AU - Vaglio, Stefania

AU - Pupella, Simonetta

AU - Mannucci, Pier Mannuccio

AU - Liumbruno, Giancarlo M.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Among the various pharmacological options to decrease peri-operative bleeding, tranexamic acid appears to be one of the most interesting. Several trials have consistently documented the efficacy of this synthetic drug in reducing the risk of blood loss and the need for allogeneic blood transfusion in patients undergoing total hip and knee arthroplasty. The safety of intravenous tranexamic acid in major orthopaedic surgery, particularly regarding the risk of venous thromboembolism, was systematically analysed in this review. A systematic search of the literature identified 73 randomised controlled trials involving 4,174 patients and 2,779 controls. The raw overall incidence of venous thromboembolism was 2.1% in patients who received intravenous tranexamic acid and 2.0% in controls. A meta-analytic pooling showed that the risk of venous thromboembolism in tranexamic acid-treated patients was not significantly different from that of controls (risk difference: 0.01%, 95% confidence interval [CI]: -0.05%, 0.07%; risk ratio: 1.067, 95% CI: 0.760-1.496). Other severe drug-related adverse events occurred very rarely (0.1%). In conclusion, the results of this systematic review and meta-analysis show that intravenous tranexamic acid is a safe pharmacological treatment to reduce blood loss and transfusion requirements in patients undergoing major orthopaedic surgery.

AB - Among the various pharmacological options to decrease peri-operative bleeding, tranexamic acid appears to be one of the most interesting. Several trials have consistently documented the efficacy of this synthetic drug in reducing the risk of blood loss and the need for allogeneic blood transfusion in patients undergoing total hip and knee arthroplasty. The safety of intravenous tranexamic acid in major orthopaedic surgery, particularly regarding the risk of venous thromboembolism, was systematically analysed in this review. A systematic search of the literature identified 73 randomised controlled trials involving 4,174 patients and 2,779 controls. The raw overall incidence of venous thromboembolism was 2.1% in patients who received intravenous tranexamic acid and 2.0% in controls. A meta-analytic pooling showed that the risk of venous thromboembolism in tranexamic acid-treated patients was not significantly different from that of controls (risk difference: 0.01%, 95% confidence interval [CI]: -0.05%, 0.07%; risk ratio: 1.067, 95% CI: 0.760-1.496). Other severe drug-related adverse events occurred very rarely (0.1%). In conclusion, the results of this systematic review and meta-analysis show that intravenous tranexamic acid is a safe pharmacological treatment to reduce blood loss and transfusion requirements in patients undergoing major orthopaedic surgery.

KW - Orthopaedic surgery

KW - Safety

KW - Thromboembolic events.

KW - Tranexamic acid

UR - http://www.scopus.com/inward/record.url?scp=85041203614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041203614&partnerID=8YFLogxK

U2 - 10.2450/2017.0219-17

DO - 10.2450/2017.0219-17

M3 - Review article

AN - SCOPUS:85041203614

VL - 16

SP - 36

EP - 43

JO - Blood Transfusion

JF - Blood Transfusion

SN - 1723-2007

IS - 1

ER -